在肝内胆管癌中,PARP-1 选择性地损害KRAS驱动的表型和分子特征
Friederike L Keggenhoff1, Darko Castven2, Diana Becker1
1First Department of Internal Medicine, University Medical Center of the Johannes Gutenberg University, Mainz, Germany.
Gut
|June 10, 2024
概括
聚 ((ADP-ribose) 聚合酶1 (PARP-1) 抑制会影响KRAS突变性肝脏内胆固醇癌 (iCCA) 的生长. 在KRAS突变iCCA中PARP-1耗尽提供了一个新的治疗策略和预后标记.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- 肝脏内胆管癌 (iCCA) 是一种普遍存在的肝癌,治疗选择有限.
- 在iCCA中,KRAS突变很常见,与糟糕的结果相关.
- 在KRAS驱动的iCCA中,Poly (ADP-ribose) 聚合酶1 (PARP-1) 的作用尚未完全理解.
研究的目的:
- 研究PARP-1在KRAS突变iCCA中的作用.
- 评估PARP-1作为iCCA中的治疗标和预后标志物.
主要方法:
- 使用RNAi,CRISPR/Cas9和iCCA细胞系 (KRAS突变和非突变) 中的药理学剂抑制PARP-1.
- 在带有诱导iCCA (Kras驱动和Kras野生型) 的Parp-1淘汰赛小鼠中进行评估.
- 在人类iCCA样本中确认临床影响.
主要成果:
- 在KRAS突变iCCA中,PARP-1表达升高.
- 在KRAS突变iCCA细胞中,PARP-1抑制显著降低了活力和瘤性.
- 失去PARP-1明显影响了iCCA表型,并取消了KRAS依赖的瘤发生,影响了DNA损伤和应激反应途径.
- 在KRAS突变iCCA中PARP-1耗尽模仿了有利的预后分子特征.
结论:
- 在KRAS驱动的iCCA中,PARP-1发挥着重要作用.
- 抑制PARP-1代表了KRAS突变的iCCA患者的潜在治疗策略.
- 在iCCA中,PARP-1 作为一种新的预后指标.
相关概念视频
The Ras Gene
6.2K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
Ras is a...
6.2K
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Interactions Between Signaling Pathways
6.3K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.3K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K


